NephCure Kidney International ®

Saving Kidneys, Saving Lives

OMS721 for Patients with IgAN

Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy

This Phase 3 study will determine is OMS721 is safe and effective at reducing symptoms for patients with IgAN. MASP-2, is a novel pro-inflammatory protein target involved in activation of the complement system, which is an important component of the immune system. Patients will be involved with the trial for about 2 years, and will take either the study medication or the placebo.

How To Contact a Study Center:

Our Mission

NephCure Kidney International’s ® mission is to accelerate research for effective treatments for rare forms of Nephrotic Syndrome, and to provide education and support that will improve the lives of those affected by these protein-spilling kidney diseases.

Sign up for our emails »

Contact Information

150 S. Warner Road
Suite 402
King of Prussia, PA 19406
1.866 NephCure (637-4287)
info@nephcure.org
EIN: 38-3569922

© Copyright 2021 NephCure Kidney International, Inc. All rights reserved worldwide. NephCure Kidney International, and the logo, are federally registered trademarks of NephCure Kidney International, Inc.